GPT and metabolic dysfunction-associated steatotic liver disease: In the current study, the FAST score decreased during pemafibrate treatment and was correlated with the variation of ALT, indicating that the hepatic anti‐inflammatory effect of pemafibrate could prevent NAFLD progression.